Deletion size characterization of der(9) deletions in Philadelphia-positive chronic myeloid leukemia

Cancer Genetics and Cytogenetics

Volumn 170, Issue 2, 2006, Pages 89-92

  Douet Guilbert, Nathalie ^a,b   Morel, Frédéric ^a,b   Quemener, Sylvia ^a   Maguer, Aurélie ^a   Le Bris, Marie Josée ^b   Morice, Patrick ^c   Berthou, Christian ^b   De Braekeleer, Marc ^a,b  

^a FACULTÉ DE MÉDECINE ET DES SCIENCES DE LA SANTÉ   (France)

^b CHU MORVAN   (France)

^c CH Yves Le Foll ^*  (France)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE;

ARTICLE; BACTERIAL ARTIFICIAL CHROMOSOME; CHROMOSOME 9; CHROMOSOME BREAKAGE; CHROMOSOME DELETION; CHROMOSOME MAP; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; PHILADELPHIA CHROMOSOME POSITIVE CELL; PRIORITY JOURNAL; PROGNOSIS; TUMOR SUPPRESSOR GENE;

CHROMOSOMES, ARTIFICIAL, BACTERIAL; CHROMOSOMES, HUMAN, PAIR 9; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE; PROTO-ONCOGENE PROTEINS C-ABL; PROTO-ONCOGENE PROTEINS C-BCR; SEQUENCE DELETION;

BACTERIA (MICROORGANISMS);

EID: 33749152100     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cancergencyto.2006.06.006     Document Type: Article

References (21)

1. Shtivelman E., Lifshitz B., Gale R.P., and Canaani E. Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature 315 (1985) 550-554
2. Kurzrock R., Shtalrid M., Talpaz M., Kloetzer W.S., and Gutterman J.U. Expression of c-abl in Philadelphia-positive acute myelogenous leukemia. Blood 70 (1987) 1584-1588
3. Sinclair P.B., Nacheva E.P., Leversha M., Telford N., Chang J., Reid A., Bench A., Champion K., Huntly B., and Green A.R. Large deletions at the t(9;22) breakpoint are common and may identify a poor-prognosis subgroup of patients with chronic myeloid leukemia. Blood 95 (2000) 738-744
4. Huntly B.J.P., Reid A.G., Bench A.J., Campbell L.J., Telford N., Shepherd P., Szer J., Prince H.M., Turner P., Grace C., Nacheva E.P., and Green A.R. Deletions of the derivative chromosome 9 occur at the time of the Philadelphia translocation and provide a powerful and independent prognostic indicator in chronic myeloid leukemia. Blood 98 (2001) 1732-1738
5. Morel F., Ka C., Le Bris M.J., Herry A., Morice P., Bourquard P., Abgrall J.F., Berthou C., and De Braekeleer M. Deletion of the 5′abl region in Philadelphia chromosome-positive chronic myeloid leukemia. Leukemia 17 (2003) 473-474
6. Morel F., Ka C., Le Bris M.J., Herry A., Morice P., Bourquard P., Abgrall J.F., Berthou C., and De Braekeleer M. Deletion of the 5′abl region in Philadelphia-positive chronic myeloid leukemia: frequency, origin and prognosis. Leuk Lymphoma 44 (2003) 1333-1338
7. Fournier M., Lacrosse S., Jamar M., Bours V., and Herens C. Deletions of the 3′BCR and 5′ABL regions in patients with Philadelphia-positive chronic myeloid leukemia: a one-step process occurring in about 10% of the cases without any evidence of genetic instability in the target cells. Cancer Genet Cytogenet 160 (2005) 184-187
8. Kolomietz E., Al-Maghrabi J., Brennan S., Karaskova J., Minkin S., Lipton J., and Squire J.A. Primary chromosomal rearrangements of leukemia are frequently accompanied by extensive submicroscopic deletions and may lead to altered prognosis. Blood 97 (2001) 3581-3588
9. Lee D.S., Lee Y.S., Yun Y.S., Kim Y.R., Jeong S.S., Lee Y.K., She C.J., Yoon S.S., Shin H.R., Kim Y., and Cho H.I. A study on the incidence of ABL gene deletion on derivative chromosome 9 in chronic myelogenous leukemia by interphase fluorescence in situ hybridization and its association with disease progression. Genes Chromosomes Cancer 37 (2003) 291-299
10. Cohen N., Rozenfeld-Granot G., Hardan I., Brok-Simoni F., Amariglio N., Rechavi G., and Trakhtenbrot L. Subgroup of patients with Philadelphia-positive chronic myelogenous leukemia characterized by a deletion of 9q proximal to ABL gene: expression profiling, resistance to interferon therapy, and poor prognosis. Cancer Genet Cytogenet 128 (2001) 114-119
11. Huntly B.J.P., Guilhot F., Reid A.G., Vassiliou G., Hennig E., Franke C., Byrne J., Brizard A., Niederwiesser D., Freeman-Edward J., Cuthbert G., Bown N., Clark R.E., Nacheva E.P., Green A.R., and Deininger M.W.N. Imatinib improves but may not fully reverse the poor prognosis of patients with CML with derivative chromosome 9 deletions. Blood 102 (2003) 2205-2212
12. Huntly B.J.P., Bench A., and Green A.R. Double jeopardy from a single translocation: deletions of the derivative chromosome 9 in chronic myeloid leukemia. Blood 102 (2003) 1160-1168
13. Quintas-Cardama A., Kantarjian H., Talpaz M., O'Brien S., Garcia-Manero G., Verstovsek S., Rios M.B., Hayes K., Glassman A., Bekele B., Zhou X., and Cortes J. Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia. Blood 105 (2005) 2281-2286
14. Specchia G., Albano F., Anelli L., Storlazzi C.T., Zagaria A., Liso A., Pannunzio A., Pastore D., Mestice A., Greco G., Liso V., and Rocchi M. Derivative chromosome 9 deletions in chronic myeloid leukemia are associated with loss of tumor suppressor genes. Leuk Lymphoma 45 (2004) 689-694
15. Anelli L., Albano F., Zagaria A., Liso A., Roberti M.G., Rocchi M., and Specchia G. A chronic myelocytic leukemia case bearing deletions on the three chromosomes involved in a variant t(9;22;11). Cancer Genet Cytogenet 148 (2004) 137-140
16. Storlazzi C.T., Specchia G., Anelli L., Albano F., Pastore D., Zagaria A., Rocchi M., and Liso V. Breakpoint characterization of der(9) deletions in chronic myeloid leukemia patients. Genes Chromosomes Cancer 35 (2002) 271-276
17. Popenoe D.W., Schaefer-Rego K., Mears J.G., Bank A., and Leibowitz D. Frequent and extensive deletion during the 9,22 translocation in CML. Blood 68 (1986) 1123-1128
18. Kolomietz E., Marrano P., Yee K., Thai B., Braude I., Kolomietz A., Chun K., Minkin S., Kamel-Reid S., Minden M., and Squire J.A. Quantitative PCR identifies a minimal deleted region of 120 kb extending from the Philadelphia chromosome ABL translocation breakpoint in chronic myeloid leukemia with poor outcome. Leukemia 17 (2003) 1313-1323
19. Silly H., Chase A., Mills K.I., Apfelbeck U., Sormann S., Goldman J.M., and Cross N.C. No evidence for microsatellite instability or consistent loss of heterozygosity at selected loci in chronic myeloid leukaemia blast crisis. Leukemia 8 (1994) 1923-1928
20. Wada C., Shionoya S., Fujino Y., Tokuhiro H., Akahoshi T., Uchida T., and Ohtani H. Genomic instability of microsatellite repeats and its association with the evolution of chronic myelogenous leukemia. Blood 83 (1994) 3449-3456
21. Huntly B.J.P., Bench A.J., Delabesse E., Reid A.G., Li J., Scott M.A., Campbell L., Byrne J., Pinto E., Brizard A., Niedermeiser D., Nacheva E.P., Guilhot F., Delninger M., and Green A.R. Derivative chromosome 9 deletions in chronic myeloid leukemia: poor prognosis is not associated with loss of ABL-BCR expression, elevated BCR-ABL levels, or karyotypic instability. Blood 99 (2002) 4547-4553